Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - News - Front Page Healthcare News - November 20, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/20/17 - "Composition and Method for Treatment of Depression and Psychosis in Humans" in Patent Application Approval Process (USPTO 20170312275)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor Javitt, Daniel C., filed on July 16, 2017, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Glytech LLC. "Diagnosis of schi
11/20/17 - "Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support
By a News Reporter-Staff News Editor at Diabetes Week Major portions of the American population with diabetes believe that their care requires much more than medicine, including emotional support and lifestyle management, and that diabetes care reimbursement needs to be broadened, according to a new survey. Diabetes 360- a Novo Nordisk- sponsored
11/20/17 - "Dual-Chamber Pack for Pharmaceutical Compositions" in Patent Application Approval Process (USPTO 20170312177)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors BHARGAVA, Rahul; MITTAL, Bhupesh Kumar, filed on May 2, 2016, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a
11/20/17 - "Low Dose Pharmaceutical Composition" in Patent Application Approval Process (USPTO 20170312254)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors MALHOTRA, Geena; PURANDARE, Shrinivas Madhukar, filed on July 14, 2017, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assi
11/20/17 - "Mission: Cure" Launched to Harness Innovative Financing and Impact Investing to Cure Disease; Pioneers New Approach by Attacking Pancreatic Disease
By a News Reporter-Staff News Editor at Clinical Trials Week The new nonprofit Mission: Cure will convene the world's leading pancreatic experts at the American Pancreatic Association meeting in San Diego on November 10th to devise a 10- year plan to cure chronic pancreatitis, a painful and costly pancreatic disease, using an innovative financing
11/20/17 - "Pharmaceutical Composition and Use Thereof" in Patent Application Approval Process (USPTO 20170312234)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventor Lin, Jung-Yaw, filed on May 2, 2016, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan Normal University.
11/20/17 - "Pyrazolo[1,5-A]pyridine Compounds and Use Thereof" in Patent Application Approval Process (USPTO 20170313697)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors Lu, Xiaoyun; Tang, Jian; Ding, Ke; Zhang, Tianyu; Zhang, Xiantao; Tu, Zhengchao; Wu, Tian; Wan, Junting; Cao, Yuanyuan; He, Shengjiang, filed on August 13, 2015, was made available online on November 9, 2017, according to news reporting originating
11/20/17 - 2017 Innovations in Whole Body Functional Imaging, Improved Patient Comfort During Mammography, Artificial Intelligence in Imaging Analytics and 3D Medical Image Visualization - Research and Markets
The "Innovations in Whole Body Functional Imaging, Improved Patient Comfort During Mammography, Artificial Intelligence in Imaging Analytics and 3 D Medical Image Visualization" newsletter has been added to Research and Markets' offering. The latest issue of Medical and Diagnostic Imaging Technologies TOE profiles innovations in medical and diagnos
11/20/17 - 2017 Innovations Supporting Medication Adherence, Hospital Staffing, Ambulatory Diagnostic Devices, and Therapies for Cardiovascular Diseases - Research and Markets
The "Innovations Supporting Medication Adherence, Hospital Staffing, Ambulatory Diagnostic Devices, and Therapies for Cardiovascular Diseases" report has been added to Research and Markets' offering. FDA- approved Vagus Nerve Stimulation Device for Epilepsy Therapy Novel Fingerstick-free Continuous Glucose Monitor Digital Stethoscope for a...
11/20/17 - 5 million will decide they no longer want free government health care if Congress scraps Obamacare
Five million people will decide they no longer want free government health care if Congress scraps Obamacare's individual mandate that currently forces them to obtain coverage, says the Congressional Budget Office. GOP lawmakers question the assumptions, wondering why those poor people who qualified for Medicaid would suddenly decide they didn't wa
11/20/17 - Absolute Analysis on Cardiovascular ultrasound Market: USD 1.72 Billion in 2023, CAGR of approximately 6.3%
Market Research Future published a Cooked research report on "Cardiovascular ultrasound Market Research Report- Global Forecast Till 2023"- Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.. Global cardiovascular ultrasound information, by type, by imaging technology by end user- Forecast to 2023. Global Cardiovascular ultrasoun
11/20/17 - Absorbable Heart Stent Market: Upcoming Demands and Growth Analysis: Global Absorbable Heart Stent Market Information, by Product Type (Polymer Based, Metal Based), by end users - Forecast to 2027
Pune, India 11/20/2017 Market Research Future adds new report of "Global Absorbable Heart Stent Market Research Report- Forecast To 2027" it contains Company information, geographical data and Table of Content. An absorbable heart stent is one that dissolves over time. The U.S. Food and Drug Administration approved the device, called Absorb,
11/20/17 - AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency...
By a News Reporter-Staff News Editor at Clinical Trials Week AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript analyzing sufentanil sublingual tablet 30 mcg for...
11/20/17 - Adocia Reports Topline Results of BioChaperone Glucagon Phase 1 Study
ADOCIA a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced top-line results of a Phase 1 study of BioChaperone Glucagon, its aqueous formulation of human glucagon. Stanislav Glezer, Adocia s Chief Medical Officer. We are currently selecting an easy-to-u
11/20/17 - Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. Ellen R. Sher, MD, is an allergist and immunologist of Allergy Partners of New Jersey, P.C., Section Chief of Allergy and Immunology at Monmo
11/20/17 - Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence
By a News Reporter-Staff News Editor at Biotech Business Week Amid one of the nation's deadliest and most significant public health crises of our time, Alkermes is calling for a formal review by the National Institutes of Health of data related to all FDA- approved medication-assisted treatment options for opioid dependence. "In the face of this
11/20/17 - Allergy Immunotherapy Market Dynamics, Comprehensive Analysis, Business Growth, Prospects and Opportunities 2016-2023: Market Research Future Issue Analysis report on Global Allergy Immunotherapy Market Research Report Forecast to 2023 Marke
Pune, India 11/20/2017 Allergy Immunotherapy market is expected to grow at the CAGR of~ 10.85% during the forecast period and is estimated to reach USD 4,324.7 million by 2023. According to the World Allergy Organization, approximately 10%-40% of the global population is suffering from allergy in 2013. The market for Allergy Immunotherapy in
11/20/17 - Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
By a News Reporter-Staff News Editor at Clinical Trials Week Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced a successful Type A meeting with the U.S. Food and Drug Administration where alignment was achieved on safety measures and a risk mitigation strategy to enable resumption of dosing in clinical studies with f
11/20/17 - Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis
CAMBRIDGE, Mass.- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis.
11/20/17 - Alnylam: FDA Grants Breakthrough Therapy Designation For Patisiran
WASHINGTON- Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, announced Monday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation or BTD for patisiran, an investigational RNAi therapeutic targeting transthyretin. Patisiran previously received Fast Track Designation in the U.S., and was recently granted
11/20/17 - Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 Biosimilar Bevacizumab For The Treatment Of Certain Types Of Cancer
By a News Reporter-Staff News Editor at Biotech Business Week Amgen and Allergan plc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin . "ABP 215 has the potential to provide healthcare profession
11/20/17 - Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate romiplostim In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
By a News Reporter-Staff News Editor at Pharma Business Week Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to expand the current indication for Nplate to include the treatment of chronic immune thrombocytopenic purpura for patients one year of age and old
11/20/17 - Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria
By a News Reporter-Staff News Editor at Pharma Business Week Artemis Therapeutics, Inc.,, a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, announced that the U.S. Food and Drug Administration granted orphan drug designation for Artemisone, the Company's lead product candidate, for the...
11/20/17 - Assisted Reproductive Technology in Fertility Clinics 2017 Global Market Expected to Grow at CAGR 4.36 % Forecast 2021
PUNE, INDIA, November 20, 2017/ EINPresswire.com/ Assisted Reproductive Technology in Fertility Clinics Market Analysis And Forecast About Assisted Reproductive Technology in Fertility Clinics Infertility is a medical condition that affects both men and women. These procedures are rendered to patients primarily in clinics, which treat infertility
11/20/17 - Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer
By a News Reporter-Staff News Editor at Cancer Vaccine Week Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax?, has received an Investigational New Drug approval from the U.S. Food and Drug Administration allowing Batu to proceed with Phase 1 clinical trials.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415